Vagner Rigaud, Ph.D.
Research Scientist II
Vagner Rigaud is a research scientist II in the Cardiovascular Disease Initiative at the Ó³»´«Ã½ of MIT and Harvard. He currently works as a project leader in the Ó³»´«Ã½-Bayer collaboration characterizing and validating novel therapeutic candidates for treatment of heart diseases.
Rigaud has been recognized with several awards including the AHA Postdoctoral Fellowship and the highly prestigious AHA Melvin L. Marcus Early Career Investigator Award.
Rigaud obtained his Ph.D. from the Heart Institute of the Universidade de São Paulo (Brazil) under the mentorship of Edimar Bocchi, evaluating circulating microRNAs as diagnostic and prognostic tools for cardiotoxicity in breast cancer patients. He received postdoctoral training at the Universidade de Coimbra (Portugal) and Temple University developing RNA-based therapeutics for heart regeneration. Rigaud also holds a M.Sc. in biomedical sciences from Universidade de São Paulo.
February 2023
